Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(11%)
Results Posted
300%(3 trials)
Terminated
2(22%)

Phase Distribution

Ph not_applicable
2
22%
Ph phase_3
2
22%
Ph phase_2
3
33%
Ph phase_1
2
22%

Phase Distribution

2

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
2(22.2%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(1)
Terminated(3)
Other(3)

Detailed Status

unknown3
Terminated2
Recruiting1
Not yet recruiting1
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (22.2%)
Phase 23 (33.3%)
Phase 32 (22.2%)
N/A2 (22.2%)

Trials by Status

recruiting111%
unknown333%
not_yet_recruiting111%
terminated222%
completed111%
withdrawn111%

Recent Activity

1 active trials
Showing 5 of 9
recruitingphase_3

TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

NCT07377032
not_yet_recruitingphase_3

Study of Serine Supplementation to Protect Vision in MacTel

NCT07342439
terminatedphase_2

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03580616
terminatedphase_2

Phase IIa L-serine Trial for eAD

NCT03062449
unknownphase_2

Hereditary Sensory Neuropathy Serine Trial

NCT06113055
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07377032Phase 3

TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

Recruiting
NCT07342439Phase 3

Study of Serine Supplementation to Protect Vision in MacTel

Not Yet Recruiting
NCT03580616Phase 2

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
NCT03062449Phase 2

Phase IIa L-serine Trial for eAD

Terminated
NCT06113055Phase 2

Hereditary Sensory Neuropathy Serine Trial

Unknown
NCT04646447Not Applicable

Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy

Unknown
NCT01733407Phase 1

L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1

Completed
NCT02528994Not Applicable

Short Term Dietary Serine Supplementation and Circulating Serine Levels

Withdrawn
NCT01835782Phase 1

Determining the Safety of L-serine in ALS

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
9